NCT03655002View on ClinicalTrials.gov

IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 21, 2019

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions
Recurrent Hepatocellular CarcinomaRefractory Liver CarcinomaStage IV Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions
DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Cytokine-based Biologic Agent IRX-2

Given SC

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (3)

75246

Texas Oncology at Baylor Charles A Sammons Cancer Center, Dallas

85258

HonorHealth Research Institute, Scottsdale

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER